Raphael Clynes
Overview
Explore the profile of Raphael Clynes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
2627
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, et al.
Blood Adv
. 2023 Aug;
7(21):6492-6505.
PMID: 37647601
Acute myeloid leukemia (AML), an aggressive malignancy with unmet medical need, lacks immunotherapeutic options. CD123, the cellular receptor for interleukin-3, expressed in AML is an attractive target for tumor-specific therapy....
2.
Parrondo R, Paulus A, Alegria V, Liebowitz D, Johnson C, Clynes R, et al.
Leuk Lymphoma
. 2021 Nov;
63(3):738-742.
PMID: 34781809
No abstract available.
3.
Perez-Lorenzo R, Erjavec S, Christiano A, Clynes R
Oncotarget
. 2021 Feb;
12(2):66-80.
PMID: 33520112
The use of specific anti-tumor antibodies has transformed the solid cancer therapeutics landscape with the relative successes of therapies such as anti-HER2 in breast cancer, and anti-EGFR in HNSCC and...
4.
Mackay-Wiggan J, Sallee B, Chun Wang E, Sansaricq F, Nguyen N, Kim C, et al.
J Am Acad Dermatol
. 2020 Oct;
84(3):841-844.
PMID: 33045294
No abstract available.
5.
de Jong A, Jabbari A, Dai Z, Xing L, Lee D, Li M, et al.
JCI Insight
. 2018 Oct;
3(19).
PMID: 30282836
Alopecia areata (AA) is an autoimmune disease in which cytotoxic T cells specifically target growing hair follicles. We used high-throughput TCR sequencing in the C3H/HeJ mouse model of AA and...
6.
Norton N, Fox N, Mccarl C, Tenner K, Ballman K, Erskine C, et al.
Breast Cancer Res
. 2018 Jun;
20(1):52.
PMID: 29898752
Background: Resected HER2 breast cancer patients treated with adjuvant trastuzumab and chemotherapy have superior survival compared to patients treated with chemotherapy alone. We previously showed that trastuzumab and chemotherapy induce...
7.
Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise J, Clark C, Ulerio G, et al.
JCI Insight
. 2016 Oct;
1(15):e89790.
PMID: 27699253
Alopecia areata (AA) is a common autoimmune disease with a lifetime risk of 1.7%; there are no FDA-approved treatments for AA. We previously identified a dominant IFN-γ transcriptional signature in...
8.
Dai Z, Xing L, Cerise J, Chun Wang E, Jabbari A, de Jong A, et al.
J Immunol
. 2016 Jul;
197(4):1089-99.
PMID: 27412416
Alopecia areata (AA) is an autoimmune disease of the hair follicle that results in hair loss of varying severity. Recently, we showed that IFN-γ-producing NKG2D(+)CD8(+) T cells actively infiltrate the...
9.
Jabbari A, Cerise J, Chen J, Mackay-Wiggan J, Duvic M, Price V, et al.
EBioMedicine
. 2016 Jun;
7:240-7.
PMID: 27322477
Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. In this study, we conducted whole genome gene expression analysis of 96 human...
10.
Knutson K, Clynes R, Shreeder B, Yeramian P, Kemp K, Ballman K, et al.
Cancer Res
. 2016 May;
76(13):3702-10.
PMID: 27197192
The addition of trastuzumab to chemotherapy extends survival among patients with HER2(+) breast cancer. Prior work showed that trastuzumab and chemotherapy augments HER2 extracellular domain (ECD)-specific antibodies. The current study...